Cosmos Health targets 2029 net income of $31 million under shift toward higher-margin proprietary brands and contract manufacturing
COSM•Cosmos Health targets 2029 revenue of $200.6 million, adjusted EBITDA of $44.2 million and net income of $31 million as it shifts toward proprietary brands and contract manufacturing.
1. Growth and financial targets
Cosmos Health plans to expand proprietary brands and contract manufacturing across its distribution network and partner markets, targeting a mix shift toward higher-margin products. It expects gross margins above 70% across key brands. The company’s 2029 goals include $200.6 million in revenue, $44.2 million in adjusted EBITDA and $31 million in net income.
2. U.S. expansion and R&D
The company’s U.S. expansion centers on the 18 Series, with domestic GMP manufacturing intended to cut lead times and reduce tariff exposure. Its R&D roadmap includes advancing CCX0722, a weight-management hydrogel capsule, pending further work and regulatory requirements.
